Torrent Pharmaceuticals Limited

BSE:500420 株式レポート

時価総額：₹1.5t

Torrent Pharmaceuticals 将来の成長

Future 基準チェック /56

Torrent Pharmaceuticals利益と収益がそれぞれ年間21.6%と16.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に26.3% 19.2%なると予測されています。

主要情報

21.6%

収益成長率

19.20%

EPS成長率

Pharmaceuticals 収益成長16.0%
収益成長率16.6%
将来の株主資本利益率26.26%
アナリストカバレッジ

Good

最終更新日27 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • Jun 04

500420: Diabetes And Obesity Portfolio Expansion Will Drive A More Upbeat Outlook

Analysts have raised their indicative fair value estimate for Torrent Pharmaceuticals from about ₹4,565 to roughly ₹4,879, reflecting expectations of steadier revenue growth, a higher profit margin, and a slightly richer future P/E assumption. What's in the News A board meeting is scheduled for 22 May 2026 to consider the audited financial results for the year ended 31 March 2026, a final dividend recommendation for 2025-26, potential fund raising via equity or convertible instruments, and other business matters.
ナラティブの更新 • May 12

500420: New Metabolic Launches And Dividend Payouts Will Shape Balanced Outlook

Analysts have nudged their fair value estimate for Torrent Pharmaceuticals from ₹4,540.32 to ₹4,564.93, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 22, 2026 to consider audited financial results for the year ended March 31, 2026 and a potential final dividend for 2025-26, along with enabling resolutions for possible equity fund raising, including convertible bonds or debentures and other modes (company filing).
ナラティブの更新 • Apr 21

500420: New Metabolic Franchise And Dividend Support Will Shape Balanced Future Outlook

Analysts have made a modest upward revision to Torrent Pharmaceuticals' price target to ₹4,540, from about ₹4,527. This reflects updated assumptions on slightly lower projected revenue growth, alongside marginally higher profit margin and future P/E expectations.
ナラティブの更新 • Apr 05

500420: New Metabolic Franchise And Dividend Plan Will Drive Future Upside

Analysts have lifted their price target on Torrent Pharmaceuticals slightly from about ₹4,499 to around ₹4,527, reflecting updated assumptions around revenue growth, profit margins and future P/E levels. What's in the News Torrent Pharmaceuticals launched its Semaglutide brands Sembolic and Semalix in India, offering both oral and injectable formulations that target metabolic disorders such as type 2 diabetes and obesity (Product announcement).
ナラティブの更新 • Mar 22

500420: Patent Dispute And Planned Dividends Will Shape Future Risk Balance

The analyst price target for Torrent Pharmaceuticals has shifted slightly higher to ₹4,498.68 from ₹4,487.96, with analysts pointing to stable assumptions around discount rate, revenue growth, profit margins, and a marginally higher future P/E multiple as the key drivers behind this refinement. What's in the News Xeris Biopharma Holdings and its subsidiaries filed a Hatch-Waxman patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics related to generic versions of Recorlev (levoketoconazole).
ナラティブの更新 • Mar 07

500420: Lawsuit And Dividend Decisions Will Shape Future Risk Balance

The updated analyst price target for Torrent Pharmaceuticals moves from roughly ₹4,418 to about ₹4,488, with analysts citing revised expectations for revenue growth and profit margins, as well as a modest adjustment in the assumed future P/E. What's in the News Xeris Biopharma Holdings filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics related to proposed generic versions of Recorlev (levoketoconazole) under the Hatch Waxman Act, seeking to block generic sales until the underlying patents, currently listed to March 2040, expire (Key Developments).
ナラティブの更新 • Feb 21

500420: Board Actions And Interim Dividend Will Shape Future Risk Balance

Analysts have revised their price target on Torrent Pharmaceuticals from ₹4,080 to ₹4,418, citing updated assumptions around revenue growth, profit margins and forward P/E as key drivers of this change. What's in the News Torrent Pharmaceuticals declared an interim dividend of ₹29 per equity share of ₹5, described as 580% of the face value, with payment or dispatch expected on or around 6 March 2026 (company announcement).
ナラティブの更新 • Feb 06

500420: Measured Growth And Board Actions Will Shape Future Risk Balance

Analysts have slightly trimmed their price target for Torrent Pharmaceuticals to reflect a lower assumed discount rate and a marginally reduced future P/E, while keeping fair value broadly unchanged and citing more measured expectations around growth and profitability. What's in the News A board meeting is scheduled for Jan 05, 2026, for the company to meet and review board matters on that date (company board communication).
ナラティブの更新 • Jan 23

500420: Patent Settlement And Margin Tweaks Will Shape Future Risk Balance

Analysts have inched up their fair value estimate for Torrent Pharmaceuticals from ₹4,048.88 to ₹4,080.22, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Torrent Pharmaceuticals has a board meeting scheduled on January 5, 2026.
ナラティブの更新 • Jan 09

500420: Patent Settlement And Margin Assumptions Will Shape Future Risk Balance

Analysts have nudged up their fair value estimate for Torrent Pharmaceuticals from ₹4,024.27 to ₹4,048.88, citing slightly stronger assumed profit margins and a marginally higher future P/E multiple in their updated models. What's in the News Torrent Pharmaceuticals has a Board Meeting scheduled on January 5, 2026, with details yet to be clarified for investors.
ナラティブの更新 • Dec 24

500420: Patent Settlement And Stable Outlook Will Shape Future Risk Profile

Narrative Update on Torrent Pharmaceuticals Analysts have maintained their price target on Torrent Pharmaceuticals at ₹4,024. This reflects unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the current fair value assessment.
ナラティブの更新 • Dec 10

500420: Patent Settlement Will Shape U S Prospects While Outlook Remains Balanced

Narrative Update on Torrent Pharmaceuticals Analysts have maintained their price target for Torrent Pharmaceuticals at ₹4,024, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margins, and future valuation multiples, despite recent model refinements. What's in the News Eisai and Torrent Pharmaceuticals reached a patent infringement settlement over Lenvima in the U.S., allowing Torrent to launch its generic lenvatinib from July 1, 2030, subject to certain contingencies (Key Developments).
ナラティブの更新 • Nov 26

500420: Patent Litigation Outcome Will Influence U S Market Path After 2030

Analysts have raised their fair value estimate for Torrent Pharmaceuticals from ₹4,010.04 to ₹4,024.27. They cited modest improvements in projected revenue growth, even though there is a slight moderation in profit margin expectations.
ナラティブの更新 • Nov 10

500420: New Settlement Agreement Will Shape U S Market Opportunity After 2030

Analysts have raised their price target for Torrent Pharmaceuticals from ₹3,929 to ₹4,010, citing slightly improved revenue growth forecasts and higher projected profit margins. What's in the News Torrent Pharmaceuticals has entered into a settlement agreement with Eisai Co., Ltd.
ナラティブの更新 • Sep 05

Robust Indian And Brazilian Markets Will Unlock Potential

With both consensus revenue growth and net profit margin forecasts holding steady, analysts kept their price target for Torrent Pharmaceuticals unchanged at ₹3929. What's in the News Shareholders approved the appointment of Aman Mehta as Managing Director for five years, following his successful tenure as Whole-time Director, where he led growth initiatives, integration of acquisitions, field force expansion, and portfolio revamps.
User avatar
新しいナラティブ • Nov 12

Driving Revenue Growth And Expanding Market Share Amid Global Challenges

Strategic restructuring and a targeted expansion could enhance market share and revenue growth, particularly in India and Brazil.

業績と収益の成長予測

BSE:500420 - アナリストの将来予測と過去の財務データ ( )INR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
3/31/2029233,85241,10653,25065,46410
3/31/2028212,80033,95050,03156,78224
3/31/2027189,56724,74937,66945,55024
3/31/2026139,79721,63423,45330,227N/A
12/31/2025127,42122,723N/AN/AN/A
9/30/2025122,48121,40313,58219,401N/A
6/30/2025118,35120,023N/AN/AN/A
3/31/2025115,16119,11319,73225,851N/A
12/31/2024113,01818,624N/AN/AN/A
9/30/2024112,23818,02429,29334,091N/A
6/30/2024109,95817,354N/AN/AN/A
3/31/2024107,27816,56428,33332,661N/A
12/31/2023104,74214,942N/AN/AN/A
9/30/2023102,33213,43224,21228,691N/A
6/30/202398,64212,692N/AN/AN/A
3/31/202396,20212,45217,94223,681N/A
12/31/202292,5808,312N/AN/AN/A
9/30/202288,7507,97215,57419,380N/A
6/30/202287,2108,012N/AN/AN/A
3/31/202285,0807,77216,00418,030N/A
12/31/202183,15812,189N/AN/AN/A
9/30/202182,02812,66915,01517,827N/A
6/30/202180,82812,609N/AN/AN/A
3/31/202180,04612,51916,70220,054N/A
12/31/202080,14312,417N/AN/AN/A
9/30/202079,85311,95713,69018,078N/A
6/30/202079,73311,297N/AN/AN/A
3/31/202079,39310,2479,86113,929N/A
12/31/201978,4885,593N/AN/AN/A
9/30/201979,3385,543N/A16,981N/A
6/30/201978,2284,893N/AN/AN/A
3/31/201976,7284,363N/A17,981N/A
12/31/201875,1418,161N/AN/AN/A
9/30/201869,8916,281N/AN/AN/A
6/30/201865,1216,531N/AN/AN/A
3/31/201859,4986,781N/A8,942N/A
12/31/201756,7276,556N/AN/AN/A
9/30/201756,3878,266N/AN/AN/A
6/30/201756,3878,296N/AN/AN/A
3/31/201758,1579,336N/A10,088N/A
12/31/201659,15410,014N/AN/AN/A
9/30/201660,14410,624N/AN/AN/A
6/30/201662,74413,644N/AN/AN/A
3/31/201666,66917,332N/A27,421N/A
12/31/201563,31516,299N/AN/AN/A
9/30/201559,60513,139N/AN/AN/A
6/30/201554,8659,439N/AN/AN/A

アナリストによる今後の成長予測

収入対貯蓄率: 500420の予測収益成長率 (年間21.6% ) は 貯蓄率 ( 6.9% ) を上回っています。

収益対市場: 500420の収益 ( 21.6% ) はIndian市場 ( 16.1% ) よりも速いペースで成長すると予測されています。

高成長収益: 500420の収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: 500420の収益 ( 16.6% ) Indian市場 ( 10.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: 500420の収益 ( 16.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 500420の 自己資本利益率 は、3年後には高くなると予測されています ( 26.3 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/08 05:34
終値2026/06/08 00:00
収益2026/03/31
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Torrent Pharmaceuticals Limited 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。48

アナリスト機関
Rohit Bhat360 ONE Capital Market Private Limited
Gaurav TinaniAmbit Capital
null nullAntique Stockbroking Ltd.